Leerink Partners analyst Andrew Berens has maintained their bullish stance on AURA stock, giving a Buy rating on April 3.
Andrew Berens’s rating is based on a combination of factors, including the recent updates from Aura Biosciences regarding their clinical trials and financial position. The company has revised its model for bel-sar, a treatment for non-muscle invasive bladder cancer (NMIBC), following new trial designs that target different patient risk groups. The potential market for bel-sar in bladder cancer has been adjusted, with peak sales now estimated at approximately $800 million, reflecting a more cautious approach to market penetration in intermediate-risk patients.
Despite the revised sales forecast, the probability of success for bel-sar has been increased to 45%, indicating confidence in the treatment’s potential efficacy. Aura Biosciences also maintains a strong financial position, with $151 million in cash and cash equivalents, providing financial stability through the second half of 2026. Additionally, ongoing enrollment for the Phase 3 trial in primary uveal melanoma and expected data releases for other trials this year contribute to the positive outlook, supporting the Buy rating with a price target of $22 per share.
According to TipRanks, Berens is an analyst with an average return of -11.3% and a 31.61% success rate. Berens covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, AstraZeneca, and Incyte.
In another report released on April 3, Scotiabank also reiterated a Buy rating on the stock with a $23.00 price target.